Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Seminars in Immunology|February 11, 2016
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Lidia Robert, Antoni Ribas, Siwen Hu-LieskovanSeminars in Oncology|May 13, 2015
Anti-PD-1 therapy in melanomaBlanca Homet Moreno, Giulia Parisi, Lidia Robert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2014
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challengesSiwen Hu-Lieskovan, Lidia Robert, Blanca Homet Moreno, et al.Archivos Espanoles De Urologia|May 8, 2013
Lytic lesions in a patient with past history of renal cancerAna Sebio, Lidia Robert, Diana Ovejero, et al.Molecular Cancer|April 17, 2014
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanomaAmanda Lassen, Mohammad Atefi, Lidia Robert, et al.Plos Computational Biology|June 6, 2019
Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistanceYapeng Su, Marcus Bintz, Yezi Yang, et al.Oncoimmunology|August 2, 2014
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytesLidia Robert, Christina Harview, Ryan Emerson, et al.Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cellsDiego Ploper, Vincent F Taelman, Lidia Robert, et al.Oncotarget|February 2, 2017
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factorSean Caenepeel, Keegan Cooke, Sarah Wadsworth, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2014
Effects of MAPK and PI3K pathways on PD-L1 expression in melanomaMohammad Atefi, Earl Avramis, Amanda Lassen, et al.Pageof 3